Literature DB >> 22198310

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy.

Katayoun Rezvani1, Agnes S M Yong, Stephan Mielke, Bipin N Savani, Behnam Jafarpour, Rhoda Eniafe, Robert Quan Le, Laura Musse, Carole Boss, Richard Childs, A John Barrett.   

Abstract

PR1, an HLA-A*0201 epitope shared by proteinase-3 (PR3) and elastase (ELA2) proteins, is expressed in normal neutrophils and overexpressed in myeloid leukemias. PR1-specific T cells have been linked to graft-versus-leukemia (GVL) effect. We hypothesized that lymphopenia induced by chemo-radiotherapy can enhance weak autoimmune responses to self-antigens such as PR1. We measured PR1-specific responses in 27 patients 30-120 days following allogeneic stem cell transplant (SCT) and correlated these with ELA2 and PR3 expression and minimal residual disease (MRD). Post-SCT 10/13 CML, 6/9 ALL, and 4/5 solid tumor patients had PR1 responses correlating with PR3 and ELA2 expression. At day 180 post-SCT, 8/8 CML patients with PR1 responses were BCR-ABL-negative compared with 2/5 BCR-ABL-positive patients (P = 0.025). In contrast, PR1 responses were detected in 2/4 MRD-negative compared with 4/5 MRD-positive ALL patients (P = 0.76). To assess whether the lymphopenic milieu also exaggerates weak T-cell responses in the autologous setting, we measured spontaneous induction of PR1 responses in 3 AML patients vaccinated with WT1-126 peptide following lymphodepletion. In addition to WT1-specific T cells, we detected PR1-specific T cells in 2 patients during hematopoietic recovery. Our findings suggest that lymphopenia induced by chemo-radiotherapy enhances weak autoimmune responses to self-antigens, which may result in GVL if the leukemia expresses the relevant self-antigen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198310      PMCID: PMC4163946          DOI: 10.1007/s00262-011-1187-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  57 in total

1.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.

Authors:  Katayoun Rezvani; Stephan Mielke; Mojgan Ahmadzadeh; Yasemin Kilical; Bipin N Savani; Josette Zeilah; Keyvan Keyvanfar; Aldemar Montero; Nancy Hensel; Roger Kurlander; A John Barrett
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

2.  Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.

Authors:  Raphaël F Rousseau; Ettore Biagi; Aurélie Dutour; Eric S Yvon; Michael P Brown; Tiffany Lin; Zhuyong Mei; Bambi Grilley; Edwina Popek; Helen E Heslop; Adrian P Gee; Robert A Krance; Uday Popat; George Carrum; Judith F Margolin; Malcolm K Brenner
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

Review 3.  Autoimmunity during lymphopenia: a two-hit model.

Authors:  Tom Krupica; Terry J Fry; Crystal L Mackall
Journal:  Clin Immunol       Date:  2006-08       Impact factor: 3.969

4.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Authors:  Peter G Maslak; Tao Dao; Lee M Krug; Suzanne Chanel; Tatyana Korontsvit; Victoria Zakhaleva; Ronghua Zhang; Jedd D Wolchok; Jianda Yuan; Javier Pinilla-Ibarz; Ellin Berman; Mark Weiss; Joseph Jurcic; Mark G Frattini; David A Scheinberg
Journal:  Blood       Date:  2010-04-16       Impact factor: 22.113

5.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.

Authors:  Hua Zhang; Kevin S Chua; Martin Guimond; Veena Kapoor; Margaret V Brown; Thomas A Fleisher; Lauren M Long; Donna Bernstein; Brenna J Hill; Daniel C Douek; Jay A Berzofsky; Charles S Carter; E J Read; Lee J Helman; Crystal L Mackall
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

6.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

Review 7.  T cell immune reconstitution following lymphodepletion.

Authors:  Kirsten M Williams; Frances T Hakim; Ronald E Gress
Journal:  Semin Immunol       Date:  2007-11-19       Impact factor: 11.130

8.  Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

Authors:  Daniela Cilloni; Aline Renneville; Fabienne Hermitte; Robert K Hills; Sarah Daly; Jelena V Jovanovic; Enrico Gottardi; Milena Fava; Susanne Schnittger; Tamara Weiss; Barbara Izzo; Josep Nomdedeu; Adrian van der Heijden; Bert A van der Reijden; Joop H Jansen; Vincent H J van der Velden; Hans Ommen; Claude Preudhomme; Giuseppe Saglio; David Grimwade
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

9.  Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity.

Authors:  K Rezvani; D A Price; J M Brenchley; Y Kilical; E Gostick; G Sconocchia; K Hansmann; R Kurlander; D C Douek; A J Barrett
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

10.  Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.

Authors:  Katayoun Rezvani; Agnes S M Yong; Bipin N Savani; Stephan Mielke; Keyvan Keyvanfar; Emma Gostick; David A Price; Daniel C Douek; A John Barrett
Journal:  Blood       Date:  2007-05-15       Impact factor: 22.113

View more
  9 in total

1.  Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Authors:  Gerrit Weber; Ignazio Caruana; Rayne H Rouce; A John Barrett; Ulrike Gerdemann; Ann M Leen; Karen R Rabin; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

Review 2.  New approaches for the immunotherapy of acute myeloid leukemia.

Authors:  Terrence L Geiger; Jeffrey E Rubnitz
Journal:  Discov Med       Date:  2015-04       Impact factor: 2.970

3.  Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.

Authors:  David A Knorr; Aaron D Goldberg; Eytan M Stein; Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2019-07-23

4.  Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines.

Authors:  Miguel-Angel Perales
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-06       Impact factor: 5.742

5.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

6.  New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.

Authors:  Lindsay Am Rein; Anthony D Sung; David A Rizzieri
Journal:  Int J Hematol Oncol       Date:  2013-02

7.  5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.

Authors:  A O Gang; T M Frøsig; M K Brimnes; R Lyngaa; M B Treppendahl; K Grønbæk; I H Dufva; P Thor Straten; S R Hadrup
Journal:  Blood Cancer J       Date:  2014-03-28       Impact factor: 11.037

Review 8.  Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.

Authors:  Olumide Babajide Gbolahan; Amer M Zeidan; Maximilian Stahl; Mohammad Abu Zaid; Sherif Farag; Sophie Paczesny; Heiko Konig
Journal:  Int J Mol Sci       Date:  2017-07-31       Impact factor: 5.923

9.  Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Authors:  Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-09       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.